

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

RPP decision paper

Review of TA297; Ocriplasmin for treating vitreomacular traction

Final recommendation post consultation
The guidance should be transferred to the 'static guidance list'

1. Background

This guidance was issued in October 2013.

At the GE meeting of 29 November 2016 it was agreed that we would consult on the recommendations made in the GE proposal paper. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

2. Proposal put to consultees and commentators

The guidance should be transferred to the 'static guidance list'.

3. Rationale for selecting this proposal

The new evidence identified from the literature searches and registered trials does not indicate that a review of the recommendations in technology appraisal 297 is needed, and the marketing authorisation and price has not changed.

4. Summary of consultee and commentator responses

Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees.

<p>Respondent: Department of Health</p> <p>Response to proposal: No comment</p> <p>No comment</p>	<p>Comment from Technology Appraisals</p> <p>Noted.</p>
-----------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------

<p>Respondent: Novartis Pharmaceuticals UK Ltd</p> <p>Response to proposal: Agree</p> <p>We agree with the guidance executive's proposal to move the guidance to the static list.</p> <p>In addition we would like to make you aware that the Marketing Authorisation for this medicine is transitioning from Alcon Laboratories UK Ltd to Novartis Pharmaceuticals UK Ltd.</p>	<p>Comment from Technology Appraisals</p> <p>Thank you for your comment. The change in Marketing Authorisation holder has also been noted.</p>
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------

Paper signed off by: Jenniffer Prescott, 01 February 2017

Contributors to this paper:

Technical Lead: Sana Khan

Project Manager: Samantha Shannon